

Resource Summary Report

Generated by [NIF](#) on Aug 3, 2026

MSCV JMJD3 mutant

RRID:Addgene_21214

Type: Plasmid

Proper Citation

RRID:Addgene_21214

Plasmid Information

URL: <http://www.addgene.org/21214>

Proper Citation: RRID:Addgene_21214

Insert Name: JMJD3

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:18628393](#)

Vector Backbone Description: Backbone Size:6300; Vector Backbone:pMSCVpuro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: MSCV JMJD3 mutant

Relevant Mutation: H1390A

Record Creation Time: 20220422T222054+0000

Record Last Update: 20260801T081015+0000

Ratings and Alerts

No rating or validation information has been found for MSCV JMJD3 mutant.

No alerts have been found for MSCV JMJD3 mutant.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mitra S, et al. (2024) A Novel Role for the Histone Demethylase JMJD3 in Mediating Heroin-Induced Relapse-Like Behaviors. *Biological psychiatry*.

Yang M, et al. (2022) KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response. *Nucleic acids research*, 50(11), 6313.

van Gils N, et al. (2022) Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persists. *iScience*, 25(9), 105013.

Yang L, et al. (2019) Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation. *Oncogenesis*, 8(1), 3.

Al Labban D, et al. (2018) Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B. *The Journal of clinical investigation*, 128(6), 2581.

Sherry-Lynes MM, et al. (2017) Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3. *PloS one*, 12(4), e0174775.

Benyoucef A, et al. (2016) UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. *Genes & development*, 30(5), 508.